Get the Stockscreener App
0.721
13.61%
-0.1181
Beyondspring Inc stock is traded at $0.721, with a volume of 294.02K.
It is down -13.61% in the last 24 hours and down -43.81% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
See More
Previous Close:
$0.8391
Open:
$0.84
24h Volume:
294.02K
Relative Volume:
0.47
Market Cap:
$29.71M
Revenue:
$1.88M
Net Income/Loss:
$-8.48M
P/E Ratio:
-3.8331
EPS:
-0.1881
Net Cash Flow:
$-19.13M
1W Performance:
-7.74%
1M Performance:
-43.81%
6M Performance:
-44.24%
1Y Performance:
-64.11%
1-Day Range:
$0.72
$0.84
1-Week Range:
$0.7201
$1.35
52-Week Range:
$0.7201
$2.44
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
0.7225 | 34.50M | 1.88M | -8.48M | -19.13M | -0.1881 |
VRTX
Vertex Pharmaceuticals Inc
|
515.67 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.59 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
993.07 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.47 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-09-21 | Initiated | Robert W. Baird | Outperform |
| Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-21 | Initiated | BofA Securities | Buy |
| Dec-29-20 | Initiated | Evercore ISI | Outperform |
| Feb-07-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Nomura | Buy |
| Dec-03-19 | Initiated | William Blair | Outperform |
| Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
| Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
BeyondSpring Inc. (BYSI) Reports Q2 Loss of $0.02 - StreetInsider
BeyondSpring (BYSI) Q2 Results Highlight Challenges Amid High Price-to-Sales Valuation - GuruFocus
BeyondSpring Cash Drops to $6.4M, Escalating Going-Concern Risk - Minichart
BeyondSpring Cash Drops to $6.5M as DUBLIN-4 Trial Funding Looms - Minichart
BeyondSpring Q2 loss narrows to $849k; EPS improves to $(0.02) - scanx.trade
BeyondSpring Inc. (BYSI) founders disclose 5.29M shares each in 13G/A - Stock Titan
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
BYSI: Net loss increased to $5.7M in Q2 2026, with urgent need for new funding amid ongoing R&D - TradingView
BeyondSpring (BYSI) posts deeper H1 2026 loss and flags going concern risk - Stock Titan
BeyondSpring Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BeyondSpring Posts $5.7 Million Second-Quarter Net Loss - Quiver Quantitative
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vascular Disrupting Agents Market - Future Market Insights
Beyondspring Inc (BYSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Pre-Revenue Biotech Reports Narrowed Loss Amid Pipeline ProgressShort-Term Outlook - dars.gov.et
Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BYSI|Beyondspring Inc|Price:0.839|Chg%:-0.157 - TradingKey
Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beyondspring Inc (BYSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beyondspring Inc (BYSI) Income Statement - TradingKey
BYSI|Beyondspring Inc|Price:1.150|Chg%:+0.030 - TradingKey
Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BYSI|Beyondspring Inc|Price:0.775|Chg%:+0.033 - TradingKey
BeyondSpring, Inc. Revenue Breakdown – NASDAQ:BYSI - TradingView
BYSI|Beyondspring Inc|Price:1.120|Chg%:+0.040 - TradingKey
Beyondspring Inc (BYSI) Institutional Confidence - TradingKey
Na (nl) Li Net Worth (2026) - GuruFocus
Min Qiu Net Worth (2026) - GuruFocus
BeyondSpring (BYSI) Q1 2026 Earnings: EPS Loss of -$0.05 Amid No Revenue and Stock DeclineGuidance vs Actual - DonanımHaber
Form 4 BeyondSpring Inc For: 6 July By Investing.com - Investing.com Nigeria
BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares - Stock Titan
BeyondSpring (BYSI) director receives 100,000 stock options grant - Stock Titan
BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing - Stock Titan
BYSI Q1 2026 Earnings: Narrowing Net Loss Reinforces Strategic FocusConsensus Miss Rate - dars.gov.et
BeyondSpring Inc. (BYSI) Edges Higher with Modest Gains, Testing Key Resistance LevelsTRIN Signal - dars.gov.et
BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Per‑Share Loss Amid Ongoing Pipeline FocusBalance Sheet Strength - dars.gov.et
BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan
BeyondSpring Inc.(NasdaqCM: BYSI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
BYSI Q1 2026 Earnings: Narrowed Loss as Pipeline AdvancesEarnings Preview - dars.gov.et
BYSI Q1 2026 Earnings: Narrowing Losses Amid Pipeline Progress, Stock Gains 5.6%Pre-Earnings Drift - dars.gov.et
Price to book forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Price to sales forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Enterprise value to revenue forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI) - TradingView
BYSI Q1 2026 Earnings: Loss Per Share Narrows as Clinical Pipeline AdvancesEPS Growth Report - dars.gov.et
BeyondSpring Inc. (BYSI) Slips 2.48%: Stock Tests Key Support at $1.49TPO Profile - dars.gov.et
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beyondspring Inc Stock (BYSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):